The prognostic value of the method for determining the estimated glomerular filtration rate in chronic heart failure with a preserved left ventricular ejection fraction: focus on cystatin C

The aim of the present study is to determine the prognostic value of GFR reduction according to the CKD-EPI formula, taking into account blood creatinine and a formula that simultaneously takes into account creatinine and cystatin C in patients who were hospitalized for the first time due to decompensation of chronic heart failure with a preserved left ventricular ejection fraction (HFSA) observation within 24 months. Materials and methods. The study included 117 patients (women – 65.8%, mean age 71.6 ± 9.1 years) hospitalized due to debugging of CHF and having a preserved left ventricular ejection fraction according to echocardiography. The study was a prospective observation for 2 years after the inclusion of each patient. On the first day of hospitalization, all serum samples were taken to determine the level of cystatin C. The estimated glomerular filtration rate (eGFR) was determined using the CKD-EPI formula, taking into account blood creatinine and the combined formula, including creatinine and cystatin C. The combination was used as an end point death and re-hospitalization within two years of follow-up. To determine the effect of a decrease in eGFR on the forecast, the Kaplan–Maer method and the log-rank test were used. Differences were considered statistically significant at p<0.05. The study was approved by the local ethics committee. Results. During the observation period, the mortality rate was almost 12%. At the same time, every third patient was repeatedly hospitalized within two years. In order to determine the effect of reducing GFR on reaching the end points, all patients were divided into groups with eGFR values of more or less than 45 ml/min/1.73 sq.m according to both formulas. When separating patients using the CKD-EPI formula, which includes only creatinine, the groups did not differ in terms of the frequency of reaching the combined end point, as well as its components: death and re-hospitalization. However, patients with eGFR values less than 45 ml/min/1.73 sq. M according to the combined formula data significantly more often reached the combined end point, mainly due to an increase in mortality. Conclusion. The data obtained suggest that adding cystatin C to the CKD-EPI formula and appropriately identifying patients with reduced eGFR has a high prognostic value for stratifying the risk of an unfavorable outcome after the first decompensation of HFSSFV.

1. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a communitybased cohort: 11-year follow-up of PREVEND. European Heart Journal. 2013;34(19):1424–31. DOI: 10.1093/eurheartj/eht066

2. Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Badin Yu.V., Galyavich A.S. et al. Prevalence of chronic heart failure in European part of Russian Federation - Data of AGE-CHF (Part II). Russian Heart Failure Journal. 2006;7(3):112–5.

3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine. 2006;355(3):251–9. DOI: 10.1056/NEJMoa052256

4. Mareev V.Yu., Danielyan M.O., Belenkov Yu.N. Comparative characteristics of patients with CHF in relation to the value of injection fraction by data from the Russian multicenter study EPOCH-A-CHF: once more about the problem of CHF with preserved left ventricular systolic function. Russian Heart Failure Journal. 2006;7(4):164–71.

5. Dikur O.N., Poltavskaia M.G., Giverts I.Yu., Doletskiy A.A., Pesheva O.V., Syrkin A.L. Ventricular-arterial coupling in case of chronic heart failure with preserved and reduced left ventricular ejection fraction. Cardiology and cardiovascular surgery. 2014;7(4):59–68.

6. Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Current Opinion in Nephrology and Hypertension. 2006;15(6):610–6. DOI: 10.1097/01.mnh.0000247505.71915.05

7. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T et al. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New England Journal of Medicine. 2012;367(1):20–9. DOI: 10.1056/NEJMoa1114248

8. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128

9. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine. 2009;150(9):604–12. DOI: 10.7326/0003-4819-150-9-200905050-00006

10. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A et al. Outcome of heart failure with preserved ejection fraction in a population-based study. The New England Journal of Medicine. 2006;355(3):260–9. DOI: 10.1056/NEJMoa051530

11. Lassus J, Harjola V-P, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. European Heart Journal. 2007;28(15):1841–7. DOI: 10.1093/eurheartj/ehl507

12. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. Journal of the American College of Cardiology. 2006;47(10):1987–96. DOI: 10.1016/j.jacc.2005.11.084

13. Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M et al. Cystatin C in Acute Heart Failure Without Advanced Renal Impairment. The American Journal of Medicine. 2009;122(6):566–73. DOI: 10.1016/j.amjmed.2008.10.042

14. Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I, MartínezMarcos FJ, Camacho-Vázquez C, Ruiz-Frutos C et al. Prognostic Value of Cystatin C on Admission in Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure. 2011;17(1):31–8. DOI: 10.1016/j.cardfail.2010.07.248

15. Huerta A, López B, Ravassa S, José GS, Querejeta R, Beloqui Ó et al. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. Journal of Hypertension. 2016;34(1):130–8. DOI: 10.1097/HJH.0000000000000757